Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would think with the sudden movement there is something in the air????!!!!
Getting bored watching DRRX drop a few cents here and there so I bought some RIGL now I can watch while I wait for good news on DRRX, at least I can go back and forth
A shake out? We'll see where it lands and pick up more shares for the next catalyst.
WHY IS DRRX DROPPING? DOES ANY BODY HAVE ANY IDEAS?
Glad to see 1.96 hold, we'll see if it's a true double bottom. My strategy of swinging to accumulate works many times. I'm not always on target but we'll see.
If the science wins then we all win. Looking forward to seeing how the next few weeks play out and into 2020.
Cheers! Glta!
BooDog
With the large number of shares I own at well under $1 I watch this stock EVERYDAY. I am waiting for the day I can jump out of my chair and proclaim I am as rich as Donald Trump and Mike Bloomberg. If the FDA approves their second try and a couple of their other hopefuls come through I will buy my own private island and coast till I fall over and c--p out.
Support held nicely. Added back in. I know most don't care about the day to day.
Another decent play is to purchase shares at present price and sell January $2.50 calls at $0.30. If they get called, you make almost 25% in 6 weeks. Also buys you downside protection to $1.90. Rare you can get near term options on a quality company with that kind of return.
You're correct. "Riding free" is taking the initial investment out and letting the potential profits stay in. If we get good data news I can put it back in for the ride up and what I left in play won't miss out. If the stock pulls back for a round of consolidation I can buy on the dip. This is how I swing trade. I don't usually post my buys and sells but sometimes I share. Not my share count but sometimes the timing and price ($2.22 yesterday). I do like DRRX's potential long term but I do like locking in some green as well.
GLTA!
Assuming he means he sold enough to get his initial investment back and is now letting the profits ride.
If so, not sure how anyone can disagree with that?
BooDog
email me at rwh0060@yahoo.com and explain to me what 'RIDING FREE" means. If it is what I think you mean I totally disagree.
Riding free now just in case it doesn't push through. Like the looks though!!
For those of you who wish to communicate with me off of the InvestorHub boards about DRRX or HRVSF I have set up a yahoo email address at rwh0060@yahoo.com
Please keep it clean and no harassment please.
SUPPLEMENTARY INFORMATION:
Agenda: The committee will discuss new drug application (NDA) 204803, bupivacaine
extended-release solution for instillation, submitted by DURECT Corp., for the proposed
indication of post-surgical analgesia. The committee will discuss whether the Applicant
adequately demonstrated the safety and efficacy of bupivacaine extended-release solution for
post-surgical analgesia and the appropriateness of the proposed patient populations. The
committee will also be asked to discuss the approvability of this product.
FDA intends to make background material available to the public no later than 2 business
days before the meeting. If FDA is unable to post the background material on its website prior to
the meeting, the background material will be made publicly available at the location of the
advisory committee meeting, and the background material will be posted on FDA’s website after
the meeting. Background material is available at
https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate
advisory committee meeting link.
Thanks for sharing bUrRpPPP!
AdCom Jan 16th for bupivacaine extended-release solution for instillation, submitted for the proposed indication of post-surgical analgesia
https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-25278.pdf
Typical buy into the anticipation and sell on the new.
* * $DRRX Video Chart 11-11-19 * *
Link to Video - click here to watch the technical chart video
Pleasant surprise today so far. I expected slow trading on no news and a holiday.So I accept the surprise and keep it up.
It looks as though with the conference call sounding VERY POSITIVE people are going to still take the attitude "SHOW ME". DURECT will have to get FDA approval to prove that they have something to gain large revenues. Personally I think this is going to happen shortly. Till then we will continue to move up a little and down a little. HOW BORING!!!!
Sounds encouraging. Thx for the update.
Oral Late-Breaking Presentation Details:
Tarek Hassanein, M.D., one of the trial’s principal investigators, will deliver the oral late-breaking presentation detailing trial results.
Title:
Safety and Efficacy of DUR-928: A Potential New Therapy for Acute Alcoholic Hepatitis
Date: Tuesday, November 12, 2019
Time: 8:30 a.m. Eastern Time
Location: Auditorium, Hynes Convention Center
Session Title: Late-Breaking Abstract Oral Session II
Presentation Type: Oral, Late-Breaking Session
Publication Number: LO9
In a separate poster presentation, Craig McClain, M.D., will present additional comparative data from the Phase 2a clinical trial of DUR-928 and a control group from a contemporaneous AH trial conducted at University of Louisville.
Poster Presentation Details:
Title: DUR-928 Therapy of Acute Alcoholic Hepatitis: A Pilot Study
Date: Sunday, November 10, 2019
Time: 12:00 – 2:00 p.m. Eastern Time
Presentation Type: Poster Presentation
Location: Hynes Convention Center, Hall B
Publication Number: 1376
We've got the cash and ready to rock.
Earnings Conference Call
We will host a conference call today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss third quarter 2019 results and provide a corporate update:
Toll Free:877-407-0784
International:201-689-8560
Conference ID:13695661
Webcast:http://public.viavid.com/index.php?id=136610
https://www.sec.gov/Archives/edgar/data/1082038/000156459019039797/drrx-ex991_6.htm
You are so right. HOPE THEY ARE ALL POSITIVE FOR EVERYONE,
Purely speculative, but can't rule out possibilities: https://finance.yahoo.com/news/gilead-cfo-lets-deal-152228514.html
8500 shares transacted in first 1/2 hr looks like a slow trading day.
Another decent day although wish we could hold back the selling in the last 1/2 hour. Tomorrow should answer a big question going through my mind, What do you think it is?????????????
I think anything under $1.80 is a steal now. The money boys were playing with it recently but I think they will allow it to do its own thing until mid to late December since the the FDA answer is now moved until Mid January. I would like to see it go up at least to $2.75 so that if they make it pull back it shouldn't go below $2/share. Of course I am way under a $1/share so I can say that.
GOOD LUCK TO ALL ON THE WAY TO $10 or more per share.
Darn. I missed out on discounted shares this morning. $1.61 is a steal deal.
The 4 million is from the offering a few months back.
You are 100% correct
Looking at most recent 13G and 13G/A it looks like First Eagle Investment Management, LLC dropped 22,476,546 shares and Bleichroeder Lp picked up 26,476,546 shares. Did they make a deal and Bleichroeder picked up a few extra after?
It looks as though the selling has mostly dried up as the stock has begun the make another upward movement. I did not hear anything shocking either way on the Cantor Fitzgerald conference earlier today to move the share price either direction.
Starts in 8 min http://wsw.com/webcast/cantor10/drrx/
We've got an excellent team leading the way.
DURECT commissioned the advisory services of Dr. Lee S. Simon to lead the Company's preparation efforts to prepare for the advisory committee meeting. Dr. Simon is a physician and research scientist who served as the FDA's Division Director of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products from 2001 to 2003, and is now a Principal at SDG, LLC, an FDA advisory firm.
"We look forward to a productive discussion with the advisory committee," stated James E. Brown, President and CEO of DURECT. "If approved, we believe that POSIMIR could help address an important need for new long-acting, non-opioid pain products in the post-operative pain setting."
Pleased to have been able to add a bit this morning.
Please explain how you came up with the idea this is bad news? I probably own 10 times the number of shares you own or more. Your title is very deceiving and borders on a SEC NO NO. I look forward to your explanation
Bad newsCUPERTINO, Calif., Oct. 2, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its Class 2 NDA resubmission for POSIMIR® (bupivacaine extended-release solution) will be discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). The meeting is tentatively scheduled for January 16, 2020. The FDA had previously assigned a user fee goal date of December 27, 2019; a new user fee goal date has not been assigned.
NCT0383774 update posted Oct 1st https://clinicaltrials.gov/ct2/history/NCT03837743?A=3&B=4&C=merged#StudyPageTop
Certainly filled the gap. Looking to pick up a few for another run.
NCT03917407 Study start date changed to Nov 1st https://clinicaltrials.gov/ct2/history/NCT03917407?A=4&B=5&C=merged#StudyPageTop
* * $DRRX Video Chart 09-23-2019 * *
Link to Video - click here to watch the technical chart video
DURECT Co. (NASDAQ: DRRX) was given a new $3.50 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
https://www.newsquantified.com/drrx/analyst-actions-report/durect-corp-was-given-a-new-350-06s8bb
Thank you DRRX for paying to replacing my central air conditioning and heating furnace[ they reached 14 years and were living on borrowed time. Nice to not have to pay out of pocket./b]
Nothing new, but NCT03432260 update formally posted today https://clinicaltrials.gov/ct2/history/NCT03432260?A=5&B=6&C=merged#StudyPageTop
Followers
|
68
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1035
|
Created
|
07/17/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |